TIDMAPH
RNS Number : 6451N
Alliance Pharma PLC
01 October 2021
For immediate release 1 October 2021
ALLIANCE PHARMA PLC
("Alliance" or the "Company")
Grant of Options to Directors
Alliance Pharma plc (AIM: APH), the international healthcare
group, announces that the Board has issued options over an
aggregate of 565,776 ordinary shares of 1 pence each in the
Company, on the recommendation of the Company's Remuneration
Committee, to the PDMRs detailed below.
Peter Butterfield, Chief Executive Officer, has been awarded
29,182 approved and 139,943 unapproved share options under the
Company's 2015 Share Option Plan; and, 180,970 share options have
been granted pursuant to the Company's Long-Term Incentive Plan
2019.
Andrew Franklin, Chief Financial Officer, has been awarded
115,000 unapproved share options under the Company's 2015 Share
Option Plan; and, 100,681 share options have been granted pursuant
to the Company's Long-Term Incentive Plan 2019.
The share options awarded under the 2015 Company Share Option
Plan have all been granted with an exercise price of 102.8p, being
the closing mid-market price on 28(th) of September 2021, and
become exercisable on 29(th) of September 2024, being the third
anniversary of the date of the grant. The awards granted under the
2019 Long Term Incentive Plan have been granted at nil-cost and
also become exercisable on 29(th) of September 2024.
The vesting of these awards is subject to continued employment
and the satisfaction of performance conditions based on EPS and TSR
targets.
The net effect of the grant of Share Options and the resultant
option holdings are shown in the table below:
Name Share Options granted Total no. of options
over ordinary shares
now held
Peter Butterfield 350,095 3,345,548
---------------------- ----------------------
Andrew Franklin 215,681 2,069,192
---------------------- ----------------------
The notification below, made in accordance with the requirements
of the UK Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by person
discharging managerial responsibilities.
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name Mr Peter Butterfield
--------------------------- -----------------------------------------------------
2 Reason for the notification
----------------------------------------------------------------------------------
a) Position/status Chief Executive Officer - PDMR
--------------------------- -----------------------------------------------------
b) Initial notification Initial Notification
/Amendment
--------------------------- -----------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------------------
a) Name Alliance Pharma plc
--------------------------- -----------------------------------------------------
b) Legal Entity N/A
Identifier
--------------------------- -----------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
----------------------------------------------------------------------------------
a) Description Ordinary shares of 1.0 pence each
of the financial ISIN: GB0031030819
instrument,
type of instrument
Identification
code
--------------------------- -----------------------------------------------------
b) Nature of the Grant of Options
transaction
--------------------------- -----------------------------------------------------
c) Currency GBP
--------------------------- -----------------------------------------------------
d) Price(s) and Exercise Price No. of share options
volume(s) (p)
--------------------------- ---------------------- -----------------------------
102.8p 169,125
-------------------------------- ---------------------- -----------------------------
Nil 180,970
---------------------- -----------------------------
e) Aggregated Grant of 169,125 options to acquire shares
information of 1p each at GBP1.028 per share at an aggregate
- Aggregated exercise value of GBP173,860.50.
volume Grant of 180,970 options to acquire ordinary
- Price shares of 1 pence each at nil-cost.
- Aggregated
total
--------------------------- -----------------------------------------------------
f) Date of the 29 September 2021
transaction
--------------------------- -----------------------------------------------------
g) Place of the Outside of trading venue
transaction
--------------------------- -----------------------------------------------------
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name Mr Andrew Franklin
--------------------------- -------------------------------------------------
2 Reason for the notification
------------------------------------------------------------------------------
a) Position/status Chief Financial Officer - PDMR
--------------------------- -------------------------------------------------
b) Initial notification Initial Notification
/Amendment
--------------------------- -------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
------------------------------------------------------------------------------
a) Name Alliance Pharma plc
--------------------------- -------------------------------------------------
b) Legal Entity N/A
Identifier
--------------------------- -------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
------------------------------------------------------------------------------
a) Description Ordinary shares of 1.0 pence each
of the financial ISIN: GB0031030819
instrument,
type of instrument
Identification
code
--------------------------- -------------------------------------------------
b) Nature of the Grant of Options
transaction
--------------------------- -------------------------------------------------
c) Currency GBP
--------------------------- -------------------------------------------------
d) Price(s) and Exercise Price No. of share options
volume(s) (p)
--------------------------- -------------------- ---------------------------
102.8p 115,000
-------------------------------- -------------------- ---------------------------
Nil 100,681
-------------------- ---------------------------
e) Aggregated Grant of 115,000 options to acquire shares
information of 1 pence each at GBP1.028 per share at an
- Aggregated aggregate exercise value of GBP118,220.
volume Grant of 100,681 options to acquire ordinary
- Price shares of 1 pence each at nil-cost.
- Aggregated
total
--------------------------- -------------------------------------------------
f) Date of the 29 September 2021
transaction
--------------------------- -------------------------------------------------
g) Place of the Outside of trading venue
transaction
--------------------------- -------------------------------------------------
For further information:
Alliance Pharma plc + 44 (0)1249 466966
Peter Butterfield, Chief Executive
Officer
Andrew Franklin, Chief Financial Officer
www.alliancepharma.co.uk
Buchanan + 44 (0)20 7466 5000
Mark Court / Sophie Wills / Hannah
Ratcliff
Numis Securities Limited + 44 (0)20 7260 1000
Nominated Adviser: Freddie Barnfield
/ Duncan Monteith
Corporate Broking: James Black
Investec Bank plc + 44 (0) 20 7597 5970
Corporate Finance: Daniel Adams
Corporate Broking: Patrick Robb
About Alliance
Alliance Pharma plc (AIM: APH) is an international healthcare
group. Our purpose is to improve the lives of consumers and
patients through making available a range of clinically valuable
healthcare products.
Our core focus is on the marketing of Consumer Healthcare
brands, complemented by a smaller Prescription Medicines business.
In total, we hold marketing rights to around 80 brands, with
revenues generated from a mix of direct, distributor and e-commerce
sales.
Headquartered in the UK, the Group employs around 250 people
based in locations across Europe, North America, and the Asia
Pacific region. By outsourcing our manufacturing and logistics
operations, we remain asset-light and focused on maximising the
value of our brands.
For more information on Alliance, please visit our website:
www.alliancepharmaceuticals.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCVBLFXFKLLBBE
(END) Dow Jones Newswires
October 01, 2021 02:00 ET (06:00 GMT)
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Apr 2023 to Apr 2024
